Background: Long-term outcomes of patients with bifurcated lesions and the restenotic response of the side branches after sirolimus-eluting stent (SES) implantation, comparing 1-stent with 2-stent treatment, are still under discussion.
ercutaneous coronary intervention (PCI) of coronary bifurcated lesions remains a major challenge even in the era of drug-eluting stents (DES). Bifurcation interventions, when compared with non-bifurcation interventions, have a lower rate of procedural success and a higher rate of restenosis regardless of the techniques or technologies used. 1-4 Furthermore, bifurcation treatment represents one of the major risk factors for stent thrombosis. 5- 8 Although stenting of non-bifurcated lesions has been shown to be superior to balloon angioplasty, stenting of both branches seems to offer no advantage over stenting of the main branch alone, and the 2-stent strategy for the treatment of bifurcation lesions has been reported as one of the major risk factors for stent thrombosis 1,9 and restenosis. 10-13 Consensus documents, which have been published by the European Bifurcation Club on the techniques favored for each bifurcation type, 14,15 recommend a provisional 2-stent strategy and place emphasis on making every attempt to avoid side-branch stenting. Although many bifurcation methods and dedicated bifurcation stents have long been proposed, most failed to prove efficacious, 16 and adequate patient selection and development of novel technologies are therefore essential to achieve safe and good outcomes in patients with bifurcated lesions.
Long-term follow-up (3 years) results and a large-scale angiographic-dedicated analysis for bifurcation using DES
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has not been reported in a real world registry setting, which may help to address better patient selection in this subset of routine therapy. Therefore, the main objectives of this study were to assess the long-term outcomes of patients with bifurcated lesions, and the angiographic restenotic response of the side branches after sirolimus-eluting stent (SES) implantation, comparing 1-stent with 2-stent strategies.
Methods

Study Design and Patient Enrollment
The CYPHER stent Japan Post-Marketing Surveillance Registry (J-PMS) is a post-marketing surveillance registry that was mandated by the Japanese government as one of the regulatory approval conditions. The primary objective of the main study is to assess the outcomes associated with SES implantation in daily clinical practice. The secondary objective is to evaluate the efficacy of SES in Japanese patients with angiographic evaluation of late loss and binary restenosis, and therefore angiographic follow up at 8 months was mandated. It was planned to consecutively enroll a total of 2,053 cases implanted with SES from September 2004 to September 2005 at 50 community-based and university hospitals that are representative of the clinical environment nationwide in Japan. Total enrollment at each site was targeted to be 20-80 patients in proportion to the site's annual volume of PCI procedures. The indications for stent implantation were left to the discretion of each cardiologist participating in the registry, including off-label use. Written informed consent was obtained for PCI with SES implantation. The main results of 1-year clinical follow up have already been published. 17 Out of this J-PMS registry, all 1,063 consecutive patients in 22 institutions were enrolled in the angiographic sub-analysis. Of these, 324 patients had bifurcation lesions as target lesions for SES implantation. Participation of angiographic sub-analysis was decided prior to the initiation of the registry by representative investigators who agreed to send angiograms to core lab on the site's basis. Angiographic sub-analysis was performed to investigate the outcomes of bifurcation lesions by means of quantitative coronary angiography (QCA). Both main and side branches were analyzed pre-and postprocedure and at 8 months. Because it was a real-world registry, there were no exclusion criteria. Bifurcation lesion was defined as a target lesion with at least 1 side branch, which requires guide-wire protection, dilatation and/or is more than 2.0 mm in diameter. The presence of bifurcation was judged by 2 experienced cardiologists at an independent core lab.
Antiplatelet Therapy
To reduce the risk of stent thrombosis, it was recommended that aspirin (81-200 mg daily) should be administered preprocedure and continued indefinitely, and ticlopidine (200 mg daily) should be administered concomitantly with aspirin and for a period of 3 months post-procedure. However, the management of antiplatelet therapy, initiation and discontinuation, Values are mean ± SD or n (%). P values were made between 1-stent and 2-stent groups. MI, myocardial infarction; CABG, coronary artery bypass graft surgery.
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including unavoidable ticlopidine discontinuation due to side effects or surgical operation, was left to the discretion of each cardiologist at participating study sites. As a result, 54.5% of the patients at 1 year and 40.5% at 3 years received dual antiplatelet therapy.
Data Collection and Management
The post-marketing surveillance databases were developed by the Japanese branch of Johnson & Johnson (Warren, NJ, USA). Detailed demographics, clinical, angiographic and procedural information including complications were gathered for each patient. Follow-up data were collected at 3, 8, 12, 24 and 36 months and thereafter yearly up to 5 years. An independent safety and efficacy evaluation committee adjudicated the following reported and suspected events: (1) major adverse cardiovascular events (MACE); defined as death, myocardial infarction (MI) and target-lesion revascularization (TLR) by PCI or by coronary artery bypass graft surgery (CABG), (2) stent thrombosis and (3) target-vessel revascularization (TVR) by PCI or CABG. The adjudications were based on the information contained in the case report form and on the responses to queries addressed to the participating study sites. Deaths were classified as cardiac-or noncardiac based on SIRIUS trial protocol definitions; therefore, unidentified death, ie, any death in which a cardiac cause could not be excluded was classified as cardiac in this study. MI was classified as Q wave and non-Q wave at the physicians' discretion on the basis of ECG changes and/or a rise in creatine kinase enzyme concentration above twice the upper normal limit. If no information was available to allow clas- 
Values are mean ± SD or n (%). ACC/AHA, American College of Cardiology/American Heart Association.
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sification of MI, it was classified as unidentified. TLR were based on the SIRIUS trial protocol definition and therefore all reported re-interventions inside the implanted stent or within 5 mm proximal or distal to the stent were classified as TLR. Repeated PCI in the same vessel but out of the target lesion was recorded as non-target lesion TVR (Non-TL TVR). Stent thrombosis was classified based on Academic Research Consortium (ARC) definitions as "Definite" or "Probable" and "Early (0-30 days after implantation)", "Late (31-360 days after implantation)" or "Very late (361-1,080 days after implantation)". 18
Angiographic Analysis
All bifurcation lesions were assessed qualitatively by 2 experienced interventional cardiologists in the independent core lab (Cardiocore Japan, Tokyo, Japan). All bifurcation lesions were classified according to the Medina classification. 19 QCA analysis was done with CAAS II for Research software (Pie Medical Imaging, Maastricht, The Netherlands) for both the main and side branches following previously described methods. 20 The target segment was defined as the entire segment involving the implanted stent and the 5-mm distal and proximal edges adjacent to the stent in the main branch. The same definition was applied to the side branches when a stent was implanted, although the proximal margin was essentially absent. Normal segment analysis was performed in the side branches without stent implantation. However, because conventional QCA algorithms may be inaccurate when applied to the measurement of side branches in terms of decisions on reference diameter (RD) and percent diameter stenosis (%DS) derived from interpolated methods if minimum lumen diameter (MLD) is located at the ostium of the side branches, to avoid overestimating diameter stenosis at the ostium of side branches, target segment was meticulously selected for the appropriate interpolated reference contour.
Statistical Analyses
Data are expressed as means ± SD for continuous variables and as frequencies for the categorical variables. For continuous variables, differences between the treatment groups were evaluated with ANOVA tests. For categorical variables, differences between the treatment groups were analyzed with Fisher's exact test or chi-square test. Event (TLR or TVR)-free survivals were analyzed by the Kaplan-Meier method and the log-rank test. Statistical significance was declared if the 2-sided probability value was <0.05. Statistical analysis was performed with JMP version 8.0 (SAS Institute, Cary, NC, USA).
Results
As already mentioned, out of a 2,053-patient cohort, 1,063 patients with 1,250 lesions were enrolled in the angiographic sub-analysis. Of these, 324 patients (30.5%) with 329 lesions including 341 side branches were eligible for the bifurcation study. Baseline patient characteristics are shown in Table 1 .
Mean age was 67.3 years and 60.5%, 44.8% and 4.9% of patients had histories of previous PCI, diabetes and hemodialysis, respectively. Acute coronary syndrome was the indication for PCI in 17.3% of patients. Lesion characteristics are listed in Table 2 , comparing main branches with side branches. Most lesions in the main branches were ACC/AHA type B2/C, whereas only 66.0% of lesions in the side branches were type B2/C. Side branches showed shorter, less calcified, less complex lesions compaed with main branches, although more than half of bifurcations were true bifurcations including significant stenosis at both branches ( Table 2 ). The majority of lesions were treated with main-branch stenting alone. Procedural characteristics are shown in Table 3 . Frequencies of use of crushing and similar techniques, Culotte and T-stent techniques were similar. Out of 324 patients, 20 patients (6.2%) also received bare metal stents for other lesions. These patients have a similar proportion and outcome to the entire cohort.
Clinical Outcomes
As shown in Table 4 , clinical follow up at 3 years was available in 300 patients (92.6%). Cardiac death occurred in 2.3%, MI in 3.7% and TLR in 10.3% of patients, resulting in a total MACE rate of 18.3%. Definite or probable stent thrombosis was observed in 2% of patients at 3 years. Death rates (both cardiac and non-cardiac) were not significantly different between the 1-stent group and the 2-stent group at 3 years. The rates of MI and TLR were significantly higher in the 2-stent group than in the 1-stent group. Therefore, MACE was observed in 16.3% of patients in the 1-stent group, which was significantly lower than in the 2-stent group (32.4%). The rates of definite or probable stent thrombosis were higher in the 2-stent group. Details of the stent thrombosis events are shown in Tables 5,6 . TLR-and TVR-free curves are depicted KOZUMA K et al.
in Figure. The 2-stent group showed higher TLR and TVR rates than the 1-stent group by the log-rank test. In the 2-stent group, final kissing balloon technique (KBT) was applied in 54.8% (23/42) of the cases. The TVR rate with final KBT was 15.0% and 29.4% in those without KBT (P=0.428).
Quantitative Angiographic Analysis
Follow-up angiography was performed in 282 lesions (85.7%). QCA results are shown in Table 7 . RD of the side branch was smaller in the 1-stent group than in the 2-stent group. MLD, RD, lesion length and %DS were different between main branch and side branch and also between side branch Values are n (%). P values were made between 1-stent and 2-stent groups. MACE, major adverse cardiovascular events; TLR, target-lesion revascularization; TVR, target-vessel revascularization; TL, target-lesion. 
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in the 1-stent group and that in the 2-stent group. In-segment binary restenosis rates at 8 months were 11.7% in the main branch and 25.6% in the side branch. However, residual significant stenosis (%DS >50%) was observed post-procedure in 31.2% of side branches. Therefore, newly developed restenosis was seen in only 6.8% of side branches in the total population. Late loss at the carina of the side branch was -0.11 mm in the 1-stent group, resulting in a larger lumen at 8 months compared with post-procedure. However, late loss in the side branch in the 2-stent group was 0.38 mm at the carina, which was larger than that seen in the 1-stent group (P<0.001), and it tended to be higher than that at main branches after side-branch stenting (0.27±0.37 mm, P=0.274).
In-stent net and acute gain in the main branch in the 2-stent group was significantly smaller than those in the 1-stent group.
Discussion
In this real-world registry, 30.5% of patients had bifurcation lesions and, as previously reported, 1-year PCI outcomes for bifurcation lesions were comparable to non-bifurcation lesions. 17 When comparing 2-stent with 1-stent treatment, the 1-stent group demonstrated superior results relative to the 2-stent group in terms of both efficacy and safety. Stent thrombosis occurred at higher rates in the 2-stent group.
Mean late loss at the side-branch carina in the 2-stent group tended to be higher than that at main branches after sidebranch stenting. In contrast, mean late loss was negative at the carina in the 1-stent group, suggesting enlargement of the lumen at 8-month follow up. Therefore, as long as it is treated with a single stent, a bifurcation lesion may not be considered among the subsets associated with worse out- KOZUMA K et al. 
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comes. If stenting of the side branch is essential to avoid complications and ischemia, patients are prone to experience more adverse events than with single stenting.
Angiographic Finding and Outcome (1-Stent vs. 2-Stent Procedures)
Restenosis rate in the main branch (6.0%) at 8 months was comparable to that of the overall population of the J-PMS registry (restenosis 13.1% in-lesion, 8.0% in-stent). 17 Side branches tended to have short and less complex lesions, which may underlie the better results seen in the 1-stent group in this real world registry. Even after unsuccessful dilatation of the side branches, the clinical impact was not significant. This was supported by the observation that a >50% stenosis was apparent in side branches after PCI in 35% of cases. It has been reported that side-branch residual stenosis was not associated with significant ischemia as judged by fractional flow reserve. 21 Similar to previous reports, 1,10-13 use of the 2-stent treatment strategy not only failed to show any benefit on clinical outcome, but rather was associated with higher rates of stent thrombosis and MI in this real world registry. Although net gain was higher in the side branch when a second stent was used, the rate of newly developed restenosis was higher in the 2-stent group than in the 1-stent group. Higher late loss in the 2-stent group may undermine the advantage of acute results at the ostium of side branches. Furthermore, acute gain and net gain were significantly smaller in the 2-stent group than in the 1-stent group in the main branch. Deformity of the main-branch stent by complex bifurcation stenting may also decrease the benefit of DES. In this regard, final KBT may reduce the risk of the side-branch stenting by reforming the main-branch stent as previously reported. 9 In the present study, the number of lesions in the 2-stent group was insufficient to demonstrate the efficacy of final KBT. Considering that dedicated bifurcation stents so far have failed to show efficacy in terms of inhibition of restenosis, a different mechanical approach should be considered to improve the outcome of bifurcation stenting.
Recently, mechanisms of under deployment or suboptimal outcome in bifurcation lesions have been published. 22, 23 An observational study with IVUS analysis of bifurcation lesions treated with the "crush" technique has shown the smallest minimum stent area at the side-branch ostium, 24 which may contribute to a higher restenosis rate. Carina shift after mainbranch stenting also contributes to the development of sidebranch stenosis, which underlies the lower success rate in side branches. Restenosis may be related to a different mechanism, and residual plaque and insufficient coverage of the side-branch ostium may play a major role in the development of side-branch restenosis. Therefore, development of restenosis is usually related to the degree of atherosclerosis in the side branch. Finally, bending and twisting of the coronary arteries at the bifurcation should be taken into account in the mechanism of side-branch restenosis because of continuous vessel wall injury by the rigid stent and potential stent fractures. 25 Bifurcation represents an extreme model of vessel bending and twisting because the vessels beyond the bifurcation are in different path/orientations and heart walls. This mechanical stress may be one of the reasons for restenosis in side branches.
Clinical Outcomes of Patients With Bifurcation Lesions
The long-term benefit of a SES compared with a bare-metal stent has been reported for on-label use. 26 TLR (10.3%) and TVR (18.3%) at 3 years in the present study seems higher than that in the overall population (TLR 7.3%, TVR 12.7%, non-TL TVR 7.3%, unpublished data). Although restenosis does not always require repeat intervention in many cases, in the side branches bifurcations usually entail 2 lesions in the cases in which the side branch needs intervention, resulting in twice the chance of experiencing restenosis. Therefore, the TLR and TVR rate seen in the present study may be acceptable in this high-risk subset of patients. The MACE-free rate up to 3 years in the present study was 81.4%, which was comparable to the 85.2% seen in the overall population in the current registry (unpublished data of J-PMS), as well as other real-world data in Japan. 27,28 Therefore, the bifurcation lesion itself may not be responsible for adverse outcomes at 3 years. In regards to the 1-stent group, the MACE-free rate was favorable and stable up to 3 years.
However, MACE rates in the 2-stent group were unacceptably high because of high TLR and MI rates. Late serious events such as death and MI may be due to mainly secondary to late and very late stent thrombosis, occurring more frequently in the 2-stent group. This finding is consistent across several clinical reports and publications on pathology observations. 13,29, 30 Bifurcations inevitably have a carina position, and 2 or 3 layers of stent metal are created when the side branch is stented without a gap at the ostium. A large quantity of metal and high-dose drugs may underlie delayed healing 31 and incomplete re-endothelialization at the stented segment. 8 However, in this study, stent thrombosis occurred at late and very late phases in patients with both complex bifurcation stenting (2 culotte and 2 crush) and single stenting, and not at the early phase. Different mechanisms such as flow turbulence and transition of shear stress may be responsible for delayed healing and thrombus formation at the bifurcation site. Use of long-term dual antiplatelet therapy should be taken into account to lower the risk of stent thrombosis including bifurcation lesions.
If the side branch is relatively large (ie, distal left main disease), severely diseased, or its occlusion is anticipated to lead to a serious adverse outcome, other treatment options such as CABG may be considered. The balance between benefit and risk is the most important consideration when planning a bifurcation intervention.
Study Limitations
Although this is one of the longest and largest studies on bifurcation lesions with angiographic follow up, the number of patients remains low to allow achievement of appropriate statistical power to assess rare events such as stent thrombosis. Interpretation of results from the subanalysis of a real-world non-randomized registry is unavoidably limited by selection bias and doctors' judgments, and therefore results of comparisons of treatment strategies in this setting are at best hypothesis-generating. In particular, the oculo-stenotic response may affect the rate of TVR. However, a lack of inclusion and exclusion criteria may provide meaningful data for patient care in routine clinical practice.
Conclusions
In a real-world setting, treatment of coronary bifurcation lesions using the SES demonstrated favorable long-term outcomes mainly due to a reduced risk of repeat revascularization at mid-term, as long as the side branch was not stented. Bifurcation lesions that require complex stenting techniques remain a concern because late and very late stent thrombosis KOZUMA K et al.
may occur more frequently than with single stenting, and the anti-restenotic effect of DES is decreased in the side branch.
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